F. Hoffmann-La Roche Ltd - Company Profile

Powered by

All the data and insights you need on F. Hoffmann-La Roche Ltd in one report.

  • Save hours of research time and resources with
    our up-to-date F. Hoffmann-La Roche Ltd Strategy Report

  • Understand F. Hoffmann-La Roche Ltd position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

F. Hoffmann-La Roche Ltd: Overview

F. Hoffmann-La Roche Ltd (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, healthcare professionals, commercial laboratories, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.

Gain a 360-degree view of F. Hoffmann-La Roche Ltd and make more informed decisions for your business Gain a 360-degree view of F. Hoffmann-La Roche Ltd and make more informed decisions for your business Find out more
Headquarters Switzerland

Address Grenzacherstrasse 124, Basel, 4070


Telephone 41 61 6919391

No of Employees 103,605

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange ROG (SWF)

Revenue (2023) $65.4B -7.2% (2023 vs 2022)

EPS XYZ

Net Income (2023) XYZ -7.4% (2023 vs 2022)

Market Cap* $214.0B

Net Profit Margin (2023) XYZ -0.3% (2023 vs 2022)

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

F. Hoffmann-La Roche Ltd premium industry data and analytics

5,700+

Clinical Trials

Determine F. Hoffmann-La Roche Ltd go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

2,500+

Catalyst Calendar

Proactively evaluate F. Hoffmann-La Roche Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

2,200+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for F. Hoffmann-La Roche Ltd’s relevant decision makers and contact details.

1,000+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

880+

Pipeline Drugs

Identify which of F. Hoffmann-La Roche Ltd’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

210+

Marketed Drugs

Understand F. Hoffmann-La Roche Ltd’s commercialized product portfolio to stay one step ahead of the market.

130+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

100+

Sales & Consensus Forecasts

Understand the current and future drug revenue for F. Hoffmann-La Roche Ltd and assess market opportunity for new entrants with patient population 8-year forecasts.

13+

Investigators

Review investigator profiles and find information on trial contacts across F. Hoffmann-La Roche Ltd, including performance indicators like number of completed trials, and linked attributes such as rehiring statistics.

13+

IT Services Contracts

Improve competitive bidding with insights into all publicly disclosed IT services contracts for F. Hoffmann-La Roche Ltd (including IT outsourcing, business process outsourcing, systems integration & consulting and more).

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on F. Hoffmann-La Roche Ltd’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Product Categories: Accu-Chek
Pharmaceuticals for: Accutrend
Anemia AmpliChip
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand F. Hoffmann-La Roche Ltd portfolio and identify potential areas for collaboration Understand F. Hoffmann-La Roche Ltd portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Contracts/Agreements In February, the company announced a collabration with Immune-Onc Therapeutics to estimate Immune-Onc’s IO-108 in combination with Roche’s atezolizumab and bevacizumab for the first-line treatment of patients with locally advanced or metastatic and unresectable hepatocellular carcinoma.
2024 Contracts/Agreements In February, the company entered into an agreement with PathAI for the creation of AI-enabled digital pathology algorithms for companion diagnostics.
2024 Acquisitions/Mergers/Takeovers In January, the company acquired Carmot Therapeutics, Inc.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters F. Hoffmann-La Roche Ltd Johnson & Johnson Merck & Co Inc Pfizer Inc AbbVie Inc
Headquarters Switzerland United States of America United States of America United States of America United States of America
City Basel New Brunswick Kenilworth New York North Chicago
State/Province - New Jersey New Jersey New York Illinois
No. of Employees 103,605 152,700 69,000 83,000 50,000
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Severin Schwan Chairman Executive Board 2023 56
Matt Sause Chief Executive Officer - Roche Diagnostics; Director Executive Board 2023 46
Thomas Schinecker Chief Executive Officer Senior Management 2023 48
Cristina A. Wilbur Chief People Officer Senior Management 2016 56
Levi Garraway Head - Global Product Development; Chief Medical Officer Senior Management - 55
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into F. Hoffmann-La Roche Ltd key executives to enhance your sales strategy Gain insight into F. Hoffmann-La Roche Ltd key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Why are you leaving?